Bioreperia

At BioReperia, we’re transforming how cancer therapies are developed and personalized. With over 55 years of world-renowned combined experience in zebrafish tumor models, and 10 years since our company's founding, our team delivers deep scientific expertise through the ZTX® platform – a fast, reliable, and CE-certified in vivo system that provides actionable results in just five days. Backed by strong validation and trusted by pharma, biotech, and clinicians, ZTX® offers a uniquely powerful, highly predictive, and cost-effective tool that provides high-resolution evaluation of tumor regression, metastasis inhibition, and immune interactions – using cell lines, PDX models, or patient-derived material. Whether you're developing small molecules or biologics, our platform empowers confident, data-driven decisions throughout the drug development pipeline. ZTX® PREDICT: Match patients with the most effective therapies to drive personalized oncology. ZTX® ONCOLEADS: Accelerate early discovery and strengthen preclinical programs with rapid, translatable efficacy data. By bridging human tumor biology with the speed and precision of ZTX® we help reduce R&D attrition, cut timelines, and increase clinical success. Let’s bring better cancer treatments to patients faster! Get in touch at info@bioreperia.com |